Cynvec
New York
About Cynvec
Cynvec, an early stage biotech company based in New York City, was created in 2004 through the spin out of exclusively licensed IP from New York University focusing on the utility of the sindbis oncolytic viral vector in the treatment of cancer. It is based on the work of Dr. Daniel Meruelo, Ph.D., the world's leading authority on the virus and professor at NYU. Cynvec is in the process of preparing an investigational new drug application (IND) for our first product, CYN 101.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.4M
- Last round: Series Unknown (Dec 2015)
- Website: cynvec.com
- Phone: +1 (732) 492.1797
Industries & Categories
Biotechnology, Health Care, Medical
Canonical: https://fsome.com/organization/cynvec-2440689 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.